Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Biologicals. 2008 Nov;36(6):346-9. doi: 10.1016/j.biologicals.2008.07.001. Epub 2008 Aug 19.

NEW technologies for meeting the global demand for pandemic influenza vaccines.

Author information

  • dfedson@wanadoo.fr

Abstract

A new influenza pandemic is expected and if caused by the H5N1 virus it could be severe. Antiviral agents will be unavailable to most people and vaccines are regarded as the mainstay of protection. Development of inactivated H5N1 vaccines has been slow because of reluctance by US regulatory authorities to consider adjuvanted formulations and the unwillingness of Western European governments to fund vaccine trials. With effective political leadership, large amounts of live-attenuated and recombinant hemagglutinin pandemic vaccines could be produced quickly in existing facilities using egg-based technologies. New types of influenza vaccines, new technologies for their production and new adjuvants to make them more immunogenic are receiving the attention of scientists and vaccine developers. These technologies could help meet the global demand for pandemic vaccines, but only if they are coupled with improvements in the human infrastructure necessary for pandemic vaccination.

PMID:
18715803
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Elsevier Science
    Loading ...
    Write to the Help Desk